The Changing Management of Low-Grade Astrocytomas and Oligodendrogliomas

Hematology/Oncology Clinics of North America

Volumn 20, Issue 6, 2006, Pages 1249-1266

  Agulnik, Mark ^a   Mason, Warren P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DISEASE CLASSIFICATION; FATIGUE; GLIOMA; HUMAN; INSOMNIA; MALAISE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTAXIC SURGERY; SURVIVAL RATE;

ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; OLIGODENDROGLIOMA; PROGNOSIS;

EID: 33750934778     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.09.003     Document Type: Review

References (83)

1. Bailey P., and Cushing H. A classification of tumours of the glioma group on a histogenetic basis with a correlated study of prognosis (1926), JB Lippincott, Philadelphia
2. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20 9 (2002) 2267-2276
3. Buatti J.M., Meeks S.L., Ryken T.C., et al. Low-grade gliomas: answering one question in a myriad of new questions. J Clin Oncol 20 9 (2002) 2223-2224
4. Hart M.N., Petito C.K., and Earle K.M. Mixed gliomas. Cancer 33 1 (1974) 134-140
5. Leibel S.A., Sheline G.E., Wara W.M., et al. The role of radiation therapy in the treatment of astrocytomas. Cancer 35 6 (1975) 1551-1557
6. Shaw E.G., Daumas-Duport C., Scheithauer B.W., et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70 6 (1989) 853-861
7. Shaw E.G., Scheithauer B.W., O'Fallon J.R., et al. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 34 4 (1994) 577-582 [discussion 82]
8. Philippon J.H., Clemenceau S.H., Fauchon F.H., et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery 32 4 (1993) 554-559
9. McCormack B.M., Miller D.C., Budzilovich G.N., et al. Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery 31 4 (1992) 636-642 [discussion 42]
10. Cavaliere R., Lopes M.B., and Schiff D. Low-grade gliomas: an update on pathology and therapy. Lancet Neurol 4 11 (2005) 760-770
11. Duffau H., and Capelle L. Preferential brain locations of low-grade gliomas. Cancer 100 12 (2004) 2622-2626
12. Laws Jr. E.R., Taylor W.F., Clifton M.B., et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 61 4 (1984) 665-673
13. Wrensch M., Minn Y., Chew T., et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol 4 4 (2002) 278-299
14. McKinney P.A. Central nervous system tumours in children: epidemiology and risk factors. Bioelectromagnetics Suppl 7 (2005) S60-S68
15. Cordier S., Mandereau L., Preston-Martin S., et al. Parental occupations and childhood brain tumors: results of an international case-control study. Cancer Causes Control 12 9 (2001) 865-874
16. Filippini G., Maisonneuve P., McCredie M., et al. Relation of childhood brain tumors to exposure of parents and children to tobacco smoke: the SEARCH international case-control study. Int J Cancer 100 2 (2002) 206-213
17. McCredie M., Little J., Cotton S., et al. SEARCH international case-control study of childhood brain tumours: role of index pregnancy and birth, and mother's reproductive history. Paediatr Perinat Epidemiol 13 3 (1999) 325-341
18. Tredaniel J., Boffetta P., Little J., et al. Exposure to passive smoking during pregnancy and childhood, and cancer risk: the epidemiological evidence. Paediatr Perinat Epidemiol 8 3 (1994) 233-255
19. Huncharek M., Kupelnick B., and Klassen H. Maternal smoking during pregnancy and the risk of childhood brain tumors: a meta-analysis of 6566 subjects from twelve epidemiological studies. J Neurooncol 57 1 (2002) 51-57
20. Pang D., McNally R., and Birch J.M. Parental smoking and childhood cancer: results from the United Kingdom Childhood Cancer Study. Br J Cancer 88 3 (2003) 373-381
21. Cordier S., Monfort C., Filippini G., et al. Parental exposure to polycyclic aromatic hydrocarbons and the risk of childhood brain tumors: the SEARCH International Childhood Brain Tumor Study. Am J Epidemiol 159 12 (2004) 1109-1116
22. Cobbs C.S., Harkins L., Samanta M., et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62 12 (2002) 3347-3350
23. Croul S., Otte J., and Khalili K. Brain tumors and polyomaviruses. J Neurovirol 9 2 (2003) 173-182
24. In: Kleihues P., and Cavenee W. (Eds). Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon (France)
25. Collins V.P. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75 Suppl 2 (2004) ii2-ii11
26. Russell D., and Rubinstein L. Pathology of tumors of the central Nervous System (1989), Williams and Wilkins, Baltimore (MD)
27. Whitton A.C., and Bloom H.J. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys 18 4 (1990) 783-786
28. Cairncross J.G., Macdonald D.R., and Ramsay D.A. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31 1 (1992) 78-82
29. Ichimura K., Bolin M.B., Goike H.M., et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60 2 (2000) 417-424
30. James C.D., Carlbom E., Nordenskjold M., et al. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 86 8 (1989) 2858-2862
31. Rasheed B.K., McLendon R.E., Herndon J.E., et al. Alterations of the TP53 gene in human gliomas. Cancer Res 54 5 (1994) 1324-1330
32. Kitange G.J., Templeton K.L., and Jenkins R.B. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 15 3 (2003) 197-203
33. Hoang-Xuan K., Merel P., Vega F., et al. Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. Int J Cancer 60 4 (1995) 478-481
34. Ichimura K., Schmidt E.E., Goike H.M., et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13 5 (1996) 1065-1072
35. Ino Y., Silver J.S., Blazejewski L., et al. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol 58 8 (1999) 881-885
36. Miyakawa A., Ichimura K., Schmidt E.E., et al. Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br J Cancer 82 3 (2000) 543-549
37. Reifenberger J., Reifenberger G., Liu L., et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145 5 (1994) 1175-1190
38. Sanson M., Thillet J., and Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 16 6 (2004) 607-613
39. Mukasa A., Ueki K., Matsumoto S., et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21 25 (2002) 3961-3968
40. von Deimling A., Louis D.N., von Ammon K., et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52 15 (1992) 4277-4279
41. Buckner J.C., Gesme Jr. D., O'Fallon J.R., et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21 2 (2003) 251-255
42. Mason W.P. Progress in clinical neurosciences: advances in the management of low-grade gliomas. Can J Neurol Sci 32 1 (2005) 18-26
43. Soffietti R., Chio A., Giordana M.T., et al. Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 24 5 (1989) 686-692
44. Vertosick Jr. F.T., Selker R.G., and Arena V.C. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28 4 (1991) 496-501
45. Bauman G., Lote K., Larson D., et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45 4 (1999) 923-929
46. Leighton C., Fisher B., Bauman G., et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15 4 (1997) 1294-1301
47. Ricci P.E., and Dungan D.H. Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol 11 2 (2001) 103-112
48. Kelly P.J., Daumas-Duport C., Scheithauer B.W., et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62 6 (1987) 450-459
49. Stack J.P., Antoun N.M., Jenkins J.P., et al. Gadolinium-DTPA as a contrast agent in magnetic resonance imaging of the brain. Neuroradiology 30 2 (1988) 145-154
50. Henson J.W., Gaviani P., and Gonzalez R.G. MRI in treatment of adult gliomas. Lancet Oncol 6 3 (2005) 167-175
51. Rock J.P., Scarpace L., Hearshen D., et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54 5 (2004) 1111-1117 [discussion 7-9]
52. Lev M.H., Ozsunar Y., Henson J.W., et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. [corrected]. AJNR Am J Neuroradiol 25 2 (2004) 214-221
53. Mineura K., Sasajima T., Kowada M., et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 73 9 (1994) 2386-2394
54. Francavilla T.L., Miletich R.S., Di Chiro G., et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24 1 (1989) 1-5
55. Berger M.S., Deliganis A.V., Dobbins J., et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74 6 (1994) 1784-1791
56. Olson J.D., Riedel E., and DeAngelis L.M. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54 7 (2000) 1442-1448
57. Karim A.B., Afra D., Cornu P., et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52 2 (2002) 316-324
58. van den Bent M.J., Afra D., de Witte O., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 9490 (2005) 985-990
59. Pignatti F., van den Bent M., Curran D., et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20 8 (2002) 2076-2084
60. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18 3 (2000) 636-645
61. Janny P., Cure H., Mohr M., et al. Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 73 7 (1994) 1937-1945
62. Kreth F.W., Faist M., Rossner R., et al. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 79 2 (1997) 370-379
63. Scerrati M., Roselli R., Iacoangeli M., et al. Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry 61 3 (1996) 291-296
64. Whittle I.R., and Beaumont A. Seizures in patients with supratentorial oligodendroglial tumours. Clinicopathological features and management considerations. Acta Neurochir (Vienna) 135 1-2 (1995) 19-24
65. Keles G.E., Lamborn K.R., and Berger M.S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95 5 (2001) 735-745
66. Karim A.B., Maat B., Hatlevoll R., et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36 3 (1996) 549-556
67. Recht L.D., Lew R., and Smith T.W. Suspected low-grade glioma: is deferring treatment safe?. Ann Neurol 31 4 (1992) 431-436
68. Kiebert G.M., Curran D., Aaronson N.K., et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer 34 12 (1998) 1902-1909
69. Laack N.N., Brown P.D., Ivnik R.J., et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63 4 (2005) 1175-1183
70. Brada M., Viviers L., Abson C., et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14 12 (2003) 1715-1721
71. Hoang-Xuan K., Capelle L., Kujas M., et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22 15 (2004) 3133-3138
72. Pace A., Vidiri A., Galie E., et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14 12 (2003) 1722-1726
73. Quinn J.A., Reardon D.A., Friedman A.H., et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21 4 (2003) 646-651
74. Soffietti R., Ruda R., Bradac G.B., et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43 5 (1998) 1066-1073
75. van den Bent M.J., Chinot O., Boogerd W., et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14 4 (2003) 599-602
76. van den Bent M.J., Taphoorn M.J., Brandes A.A., et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21 13 (2003) 2525-2528
77. Danson S.J., and Middleton M.R. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 1 1 (2001) 13-19
78. Stege E.M., Kros J.M., de Bruin H.G., et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103 4 (2005) 802-809
79. Macdonald D.R., Gaspar L.E., and Cairncross J.G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27 5 (1990) 573-574
80. Mason W.P., Krol G.S., and DeAngelis L.M. Low-grade oligodendroglioma responds to chemotherapy. Neurology 46 1 (1996) 203-207
81. Cairncross G., Seiferheld W., Shaw E., et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02. J Clin Oncol 22 14S (2004) 1500
82. Baumert B.G., Stupp R., van den Bent M., et al. Therapy with continuous temozolomide for low grade glioma, inclusion based on genetic classification: two study proposals of the EORTC (European Organization for Research and Treatment of Cancer). Neuro-oncology 4 Suppl 1 (2002) 57
83. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996